Michael Fralick1, Michael Colacci2, Sebastian Schneeweiss3, Krista F Huybrechts3, Kueiyu Joshua Lin3, Joshua J Gagne3. 1. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, and Sinai Health System and University of Toronto, Toronto, Ontario, Canada (M.F.). 2. Sinai Health System and University of Toronto, Toronto, Ontario, Canada (M.C.). 3. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (S.S., K.F.H., K.J.L., J.J.G.).
Abstract
Background: Apixaban and rivaroxaban are the most commonly prescribed direct oral anticoagulants for adults with atrial fibrillation, but head-to-head data comparing their safety and effectiveness are lacking. Objective: To compare the safety and effectiveness of apixaban versus rivaroxaban for patients with nonvalvular atrial fibrillation. Design: New-user, active-comparator, retrospective cohort study. Setting: A U.S. nationwide commercial health care claims database from 28 December 2012 to 1 January 2019. Patients: Adults newly prescribed apixaban (n = 59 172) or rivaroxaban (n = 40 706). Measurements: The primary effectiveness outcome was a composite of ischemic stroke or systemic embolism. The primary safety outcome was a composite of intracranial hemorrhage or gastrointestinal bleeding. Results: 39 351 patients newly prescribed apixaban were propensity score matched to 39 351 patients newly prescribed rivaroxaban. Mean age was 69 years, 40% of patients were women, and mean follow-up was 288 days for new apixaban users and 291 days for new rivaroxaban users. The incidence rate of ischemic stroke or systemic embolism was 6.6 per 1000 person-years for adults prescribed apixaban compared with 8.0 per 1000 person-years for those prescribed rivaroxaban (hazard ratio [HR], 0.82 [95% CI, 0.68 to 0.98]; rate difference, 1.4 fewer events per 1000 person-years [CI, 0.0 to 2.7]). Adults prescribed apixaban also had a lower rate of gastrointestinal bleeding or intracranial hemorrhage (12.9 per 1000 person-years) compared with those prescribed rivaroxaban (21.9 per 1000 person-years), corresponding to an HR of 0.58 (CI, 0.52 to 0.66) and a rate difference of 9.0 fewer events per 1000 person-years (CI, 6.9 to 11.1). Limitation: Unmeasured confounding, incomplete laboratory data. Conclusion: In routine care, adults with atrial fibrillation prescribed apixaban had a lower rate of both ischemic stroke or systemic embolism and bleeding compared with those prescribed rivaroxaban. Primary Funding Source: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital.
Background: Apixaban and rivaroxaban are the most commonly prescribed direct oral anticoagulants for adults with atrial fibrillation, but head-to-head data comparing their safety and effectiveness are lacking. Objective: To compare the safety and effectiveness of apixaban versus rivaroxaban for patients with nonvalvular atrial fibrillation. Design: New-user, active-comparator, retrospective cohort study. Setting: A U.S. nationwide commercial health care claims database from 28 December 2012 to 1 January 2019. Patients: Adults newly prescribed apixaban (n = 59 172) or rivaroxaban (n = 40 706). Measurements: The primary effectiveness outcome was a composite of ischemic stroke or systemic embolism. The primary safety outcome was a composite of intracranial hemorrhage or gastrointestinal bleeding. Results: 39 351 patients newly prescribed apixaban were propensity score matched to 39 351 patients newly prescribed rivaroxaban. Mean age was 69 years, 40% of patients were women, and mean follow-up was 288 days for new apixaban users and 291 days for new rivaroxaban users. The incidence rate of ischemic stroke or systemic embolism was 6.6 per 1000 person-years for adults prescribed apixaban compared with 8.0 per 1000 person-years for those prescribed rivaroxaban (hazard ratio [HR], 0.82 [95% CI, 0.68 to 0.98]; rate difference, 1.4 fewer events per 1000 person-years [CI, 0.0 to 2.7]). Adults prescribed apixaban also had a lower rate of gastrointestinal bleeding or intracranial hemorrhage (12.9 per 1000 person-years) compared with those prescribed rivaroxaban (21.9 per 1000 person-years), corresponding to an HR of 0.58 (CI, 0.52 to 0.66) and a rate difference of 9.0 fewer events per 1000 person-years (CI, 6.9 to 11.1). Limitation: Unmeasured confounding, incomplete laboratory data. Conclusion: In routine care, adults with atrial fibrillation prescribed apixaban had a lower rate of both ischemic stroke or systemic embolism and bleeding compared with those prescribed rivaroxaban. Primary Funding Source: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital.
Authors: Benjamin J R Buckley; Deirdre A Lane; Peter Calvert; Juqian Zhang; David Gent; C Daniel Mullins; Paul Dorian; Shun Kohsaka; Stefan H Hohnloser; Gregory Y H Lip Journal: J Clin Med Date: 2022-06-30 Impact factor: 4.964
Authors: Wayne A Ray; Cecilia P Chung; C Michael Stein; Walter Smalley; Eli Zimmerman; William D Dupont; Adriana M Hung; James R Daugherty; Alyson Dickson; Katherine T Murray Journal: JAMA Date: 2021-12-21 Impact factor: 157.335
Authors: Alfredo Jose Pardo-Cabello; Victoria Manzano-Gamero; Juan de Dios Luna Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2021-03-05 Impact factor: 3.000
Authors: Stine Munk Hald; Sören Möller; Luis Alberto García Rodríguez; Rustam Al-Shahi Salman; Mike Sharma; Hanne Christensen; Maja Hellfritzsch; Anton Pottegård; Jesper Hallas; David Gaist Journal: JAMA Netw Open Date: 2021-05-03
Authors: Sylvie Perreault; Alice Dragomir; Robert Côté; Aurélie Lenglet; Simon de Denus; Marc Dorais; Brian White-Guay; James Brophy; Mireille E Schnitzer; Marie-Pierre Dubé; Jean-Claude Tardif Journal: Front Pharmacol Date: 2022-01-14 Impact factor: 5.810
Authors: Samiullah Arshad; George A Davis; Muhammad Amir; Ythan H Goldberg; Vedant A Gupta; Ahmed K Abdel-Latif; Susan Smyth Journal: Cardiol Res Date: 2022-03-12
Authors: Hendrika A van den Ham; Patrick C Souverein; Olaf H Klungel; Robert W Platt; Pierre Ernst; Sophie Dell'Aniello; Sven Schmiedl; Birgit Grave; Marietta Rottenkolber; Consuelo Huerta; Elisa Martín Merino; Luz M León-Muñoz; Dolores Montero; Morten Andersen; Mia Aakjaer; Marie L De Bruin; Helga Gardarsdottir Journal: Pharmacoepidemiol Drug Saf Date: 2021-07-22 Impact factor: 2.890